Citrate Versus Heparin for the Lock of Non-tunneled Hemodialysis Catheters in Patients Hospitalised in ICU

NCT01962116 | Completed Phase 3

• 1 other identifier: QUENOT DB 2012
• Study Type: interventional
• Target: 405
• Locations: 1 country
• Sites: 1

Brief Summary

After obtaining written informed consent and inclusion, patients will be randomised into 2 groups for the type of dialysis catheter lock:

• The first group will have a citrate lock
• The second group will have a heparin lock Patients will be stratified according to the centre and type of Renal Replacement Therapy (RRT) continuous or intermittent. The daily surveillance of patients will not be different from the usual surveillance of patients on Renal Replacement Therapy. The hemodialysis catheters used will be specific Renal Replacement Therapy catheters. The decision to withdraw the catheter will be made by the investigator and based on clinical criteria (complications related to the catheter, termination of Renal Replacement Therapy…)

Conditions

Patients With Acute Renal Insufficiency

Outcome Measures

Primary Outcomes (1)

• Duration of event-free survival of the first non-tunneled hemodialysis catheter (defined at the time in days from catheter insertion to withdrawal whatever the reason)

  up to 28 days

Study Arms (2)

Heparin lock

PLACEBO COMPARATOR

Drug: unfractionated heparin

Citrate lock

EXPERIMENTAL

Drug: Citrate 4%

Interventions

Citrate 4% DRUG

Citrate lock

unfractionated heparin DRUG

Heparin lock

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients aged \> 18 years
• Requiring RRT for acute renal insufficiency
• For which a 1st non-tunneled catheter is placed
• In the jugular or femoral position
• After written informed consent has been obtained from the patient, a member of the family or a person of trust

You may not qualify if:

• Patient presenting active poorly controlled bleeding
• Known allergy to citrate
• Acute liver failure (Prothrombin level \<30%)
• Thrombopenia \< 30 000/mm3
• Known or suspected heparin-induced thrombopenia
• Known systemic bacterial infection at the time the catheter is placed
• catheter in the subclavicular position
• Persons not affiliated to a national health insurance scheme
• Pregnant women
• Adults under guardianship

Sponsors & Collaborators

• Centre Hospitalier Universitaire Dijon: lead

Study Sites (1)

CHU Dijon

Dijon, 21000, France

Location

Related Publications (3)

• Quenot JP, Helms J, Bourredjem A, Dargent A, Meziani F, Badie J, Blasco G, Piton G, Capellier G, Mezher C, Rebibou JM, Nadji A, Crepin T, Barbar SD, Fleck C, Cransac A, Boulin M, Binquet C, Soudry-Faure A, Bruyere R; VERROU-REA Trial Investigators and the CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis). Trisodium citrate 4% versus heparin as a catheter lock for non-tunneled hemodialysis catheters in critically ill patients: a multicenter, randomized clinical trial. Ann Intensive Care. 2019 Jul 1;9(1):75. doi: 10.1186/s13613-019-0553-4.

  PMID: 31264073 RESULT

• Tsujimoto H, Tsujimoto Y, Nakata Y, Fujii T, Takahashi S, Akazawa M, Kataoka Y. Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy. Cochrane Database Syst Rev. 2020 Dec 14;12(12):CD012467. doi: 10.1002/14651858.CD012467.pub3.

  PMID: 33314078 DERIVED

• Bruyere R, Soudry-Faure A, Capellier G, Binquet C, Nadji A, Torner S, Blasco G, Yannaraki M, Barbar SD, Quenot JP. Comparison of heparin to citrate as a catheter locking solution for non-tunneled central venous hemodialysis catheters in patients requiring renal replacement therapy for acute renal failure (VERROU-REA study): study protocol for a randomized controlled trial. Trials. 2014 Nov 19;15:449. doi: 10.1186/1745-6215-15-449.

  PMID: 25409678 DERIVED

MeSH Terms

Interventions

Heparin

Intervention Hierarchy (Ancestors)

Glycosaminoglycans; Polysaccharides; Carbohydrates

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 27, 2013
• First Posted: October 14, 2013
• Study Start: June 14, 2013
• Primary Completion: April 1, 2016
• Study Completion: December 31, 2016
• Last Updated: February 9, 2026

Record last verified: 2026-02

Locations

FR (1)